Sign in
Taking people in NetherlandsPhase 4

Personal statin trials for people with side effects and high heart risk

Tests personal statin trials in adults with statin intolerance and high heart risk.

Key facts

Who runs it
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Where
Amersfoort, Arnhem, Dordrecht, Ede Gld, Nijmegen, Rotterdam, Tilburg, Utrecht, and Zwolle, NetherlandsSee the 11 sites
Registry title
Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance
Status
Recruiting
Phase
Phase 4
People taking part
249 people, planned
Started
10 Dec 2024
Expected to end
31 Jul 2030
Type of study
Interventional
Record updated
27 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart disease or familial hypercholesterolemia who stopped statins because of side effects, to test whether an n=1 study helps them take statins again.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Previous cardiovascular disease, or familial hypercholesterolemia (both primary and secondary prevention), with a need for cholesterol-lowering treatment.
Earlier treatment
Must have taken two or more statins and stopped them because of (perceived) side effects.

Main reasons for not taking part

  • Previous statin use that caused a severe allergic reaction, muscle damage, abnormal liver tests or other severe health problems
  • Pregnancy, planned pregnancy within 12 months, or breastfeeding
  • History of muscle disease, long-lasting severe pain, severe mental illness, cirrhosis or severe kidney problems
  • A cardiovascular event in the past 3 months
  • No digital access, or not enough Dutch or English to fill in the questionnaires

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Aged 18 years or older
  • Previously taken two or more statins and withdrawn from statins because of (perceived) side effects
  • Clinical indication for lipid lowering therapy related to secondary prevention of cardiovascular disease (previous CVD) or prevention of cardiovascular disease (both primary and secondary) in familial hypercholesterolemia
  • Provided full informed consent

Who cannot take part

  • Clinical judgement of the health care professional that LDL-c lowering therapy cannot be withheld in a patient with a recent cardiovascular event in the past 12 months
  • History of myopathy or any other condition that causes severe chronic pain
  • History of severe mental illness (as their experience of symptoms may already be altered)
  • Clinical judgement of the health care professional that LDLc-lowering therapy is not relevant for the prognosis (e.g. severe frailty, dementia, end-stage heart failure, end-stage malignancy)
  • A contra-indication for rosuvastatin therapy related to: a. Previous statin use causing anaphylaxis or other moderate/severe allergic reaction. b. Previous statin use causing myopathy (serum rise of creatine kinase more than 3 times the upper limit of normal) or rhabdomyolysis. c. Previous statin use with liver function abnormalities, defined as aspartate aminotransferase (AST) or alanine aminotransferase >3 times the upper limit of normal. d. Previous statins use causing severe health issues. e. Planned pregnancy within 12 months, pregnancy or breastfeeding. f. Currently taking other drugs with known relevant interactions to rosuvastatin as listed in the Investigational Medicinal Product Dossier (IMPD). g. Any other contraindication for rosuvastatin as listed in the Investigational Medicinal Product Dossier (IMPD)
  • History of cirrhosis or severe renal insufficiency (eGFR < 20 ml/min/1,73m2)
  • Insufficient ability to fill in questionnaires in the digital platform; a. No access to a smartphone, tablet or personal computer. b. Insufficient understanding of the Dutch or English language
  • A recent cardiovascular event in the past 3 months
  • Clinical judgement of the health care professional who considers participation unethical or otherwise unwanted

Where in Netherlands

  • Meander Medisch CentrumAmersfoort, NetherlandsTaking people
  • Rijnstate Ziekenhuis StichtingArnhem, NetherlandsTaking people
  • Albert Schweitzer ZiekenhuisDordrecht, NetherlandsTaking people
  • Ziekenhuis Gelderse Vallei StichtingEde Gld, NetherlandsTaking people
  • Radboud Universitair Medisch Centrum (Radboudumc)Nijmegen, NetherlandsTaking people
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
  • Maasstad Ziekenhuis StichtingRotterdam, NetherlandsTaking people
  • Sint Franciscus Vlietland Groep StichtingRotterdam, NetherlandsTaking people
  • Stichting Elisabeth-TweeSteden ZiekenhuisTilburg, NetherlandsTaking people
  • Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
  • Isala Klinieken StichtingZwolle, NetherlandsTaking people

About the trial

What the trial wants to find out

The key objective of the study is to assess whether an ‘n=1 study’ (randomized, double blind, cross-over trial with counseling on patients’ individual treatment results) will increase statin use and reduce the prescription of PCSK9i compared to usual care at 12 months (t12m) after randomization.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
N=1-studies In Statin-intolerance; Objectifying Nocebo Effects (NISONE)
Plain-language title
Personal statin trials for people with side effects and high heart riskGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
27 August 2026